{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:40:12Z","timestamp":1787928012465,"version":"build-2784847793"},"reference-count":104,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.annonc.2026.01.012","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:32:14Z","timestamp":1770078734000},"page":"624-638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Progress in targeting the untouchables: emerging approaches for hard-to-drug cancer targets"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-9528","authenticated-orcid":false,"given":"N.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1200-9095","authenticated-orcid":false,"given":"H.N.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"J.","family":"Rodon Ahnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 12","key":"10.1016\/j.annonc.2026.01.012_bib1","article-title":"Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: the ReFocus study","volume":"22","author":"Schram","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.01.012_bib2","article-title":"A multicenter, open-label, first-in-human study of TYRA-200 in advanced intra- hepatic cholangiocarcinoma and other solid tumors with activating FGFR2 gene alterations (SURF201)","volume":"43","author":"Ahnert","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.012_bib3","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/2159-8290.CD-23-0945","article-title":"A new wave of PI3K\u03b1 inhibitors","volume":"13","author":"Kearney","year":"2023","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.012_bib4","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1158\/2159-8290.CD-23-0396","article-title":"STX-478, a mutant-selective, allosteric PI3K\u03b1 inhibitor spares metabolic dysfunction and improves therapeutic response in PI3K\u03b1-mutant xenografts","volume":"13","author":"Buckbinder","year":"2023","journal-title":"Cancer Discov"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2026.01.012_bib5","article-title":"Abstract OT3-22-01: First-in-human global multi-center study of RLY-2608, a pan mutant and isoform selective PI3K\u03b1 inhibitor, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with advanced breast cancer","volume":"83","author":"Varkaris","year":"2023","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.annonc.2026.01.012_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2026.01.012_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.01.012_bib8","first-page":"1","article-title":"Taking aim at the undruggable","volume":"41","author":"Coleman","year":"2021","journal-title":"Am Soc Clin Oncol Educ B"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets Europe PMC Funders Group","volume":"16","author":"Santos","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2026.01.012_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","article-title":"Targeting oncogenic Myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.012_bib13","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/1535-7163.MCT-22-0356","article-title":"The next generation of KRAS targeting: reasons for excitement and concern","volume":"21","author":"Akhave","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.annonc.2026.01.012_bib15","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2026.01.012_bib16","article-title":"Targeting Wnt\/\u03b2-catenin pathway for drug therapy","volume":"8","author":"Liu","year":"2020","journal-title":"Med Drug Discov"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.012_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","article-title":"Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond \u03b2-catenin and the destruction complex","volume":"52","author":"Jung","year":"2020","journal-title":"Exp Mol Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.012_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10555-020-09887-6","article-title":"Wnts and the hallmarks of cancer","volume":"39","author":"Zhong","year":"2020","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"10.1016\/j.annonc.2026.01.012_bib19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","article-title":"YAP\/TAZ upstream signals and downstream responses","volume":"20","author":"Totaro","year":"2018","journal-title":"Nat Cell Biol"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.012_bib20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.annonc.2026.01.012_bib21","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/ncomms7051","article-title":"The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors","volume":"6","author":"Zingg","year":"2015","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.annonc.2026.01.012_bib22","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-12-0036","article-title":"TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep)","volume":"18","author":"Cheng","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.annonc.2026.01.012_bib23","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1182\/blood.V128.22.4203.4203","article-title":"A phase I study of GSK2816126, an enhancer of zeste homolog 2(EZH2) inhibitor, in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL), other non-Hodgkin lymphomas (NHL), transformed follicular lymphoma (tFL), solid tumors and mul","volume":"128","author":"Yap","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.annonc.2026.01.012_bib24","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-18-2395","article-title":"EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells","volume":"79","author":"Huang","year":"2019","journal-title":"Cancer Res"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.01.012_bib25","article-title":"A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)","volume":"40","author":"Hong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2026.01.012_bib26","article-title":"KRYSTAL-12: a randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRAS G12C mutation","volume":"39","author":"Mok","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 17","key":"10.1016\/j.annonc.2026.01.012_bib27","article-title":"KRYSTAL-12: phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"42","author":"Mok","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.01.012_bib28","unstructured":"Li BT, Skoulidis F, Falchook G, et al. CodeBreak 100: registrational phase 2 trial of sotorasib in KRAS p.G12C mutated non-small cell lung cancer. 2020 World Conference on Lung Cancer Abstract PS0107."},{"issue":"25","key":"10.1016\/j.annonc.2026.01.012_bib29","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS G12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"issue":"8 suppl 2","key":"10.1016\/j.annonc.2026.01.012_bib30","article-title":"Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors","volume":"85","author":"Arbour","year":"2025","journal-title":"Cancer Res"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.01.012_bib31","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2025.43.4_suppl.724","volume":"43","author":"Spira","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41421-024-00699-4","article-title":"A pan-KRAS degrader for the treatment of KRAS-mutant cancers","volume":"10","author":"Yang","year":"2024","journal-title":"Cell Discov"},{"issue":"6715","key":"10.1016\/j.annonc.2026.01.012_bib33","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"suppl 8","key":"10.1016\/j.annonc.2026.01.012_bib34","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1158\/1538-7445.AM2025-7010","article-title":"HDB-82: a promising PROTAC degrader for KRAS G12D mutant cancers","volume":"85","author":"Baig","year":"2025","journal-title":"Cancer Res"},{"issue":"8 suppl 1","key":"10.1016\/j.annonc.2026.01.012_bib35","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1538-7445.AM2025-1662","article-title":"Abstract 1662: Preclinical studies of RP04340: an orally available and potent PROTAC compound targeting KRAS G12C\/D\/V mutant tumors","volume":"85","author":"Ji","year":"2025","journal-title":"Cancer Res"},{"issue":"8 suppl 1","key":"10.1016\/j.annonc.2026.01.012_bib36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1158\/1538-7445.AM2025-397","article-title":"Abstract 397: Combinatorial use of VHL and KEAP1-based PROTACs reveals unexpected synergy and hook effect relief","volume":"85","author":"Islam","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.01.012_bib37","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ccell.2025.05.006","article-title":"Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy","volume":"43","author":"Benton","year":"2025","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.012_bib38","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2026.01.012_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103756","article-title":"Therapeutic targeting of \u201cundruggable\u201d MYC","volume":"75","author":"Llombart","year":"2022","journal-title":"eBioMedicine"},{"issue":"12","key":"10.1016\/j.annonc.2026.01.012_bib40","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/s41416-020-01077-z","article-title":"First-in-human phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours","volume":"123","author":"Ameratunga","year":"2020","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.012_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41389-020-0218-z","article-title":"BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2\/NID1 signaling","volume":"9","author":"Zhou","year":"2020","journal-title":"Oncogenesis"},{"issue":"30","key":"10.1016\/j.annonc.2026.01.012_bib42","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.01.012_bib43","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.012_bib44","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","article-title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","volume":"30","author":"Garralda","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.012_bib45","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-022-00348-3","article-title":"Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome","volume":"3","author":"Golbourn","year":"2022","journal-title":"Nat Cancer"},{"issue":"6278","key":"10.1016\/j.annonc.2026.01.012_bib46","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"6278","key":"10.1016\/j.annonc.2026.01.012_bib47","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.annonc.2026.01.012_bib48","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-25-2126","article-title":"MTAP deletion in oncogenesis: a new synthetic lethality scenario","author":"Rodon","year":"2026","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","article-title":"Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss","volume":"36","author":"Fedoriw","year":"2019","journal-title":"Cancer Cell"},{"issue":"suppl 12","key":"10.1016\/j.annonc.2026.01.012_bib50","article-title":"Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors","volume":"22","author":"Rodon","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.012_bib51","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/acs.jmedchem.4c03067","article-title":"Discovery of TNG462: a highly potent and selective MTA-cooperative PRMT5 inhibitor to target cancers with MTAP deletion","volume":"68","author":"Cottrell","year":"2025","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.012_bib52","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.annonc.2026.01.012_bib53","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c00133","article-title":"Discovery of TNG908: a selective, brain penetrant, MTA-cooperative PRMT5 inhibitor that is synthetically lethal with MTAP-deleted cancers","volume":"67","author":"Cottrell","year":"2024","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.annonc.2026.01.012_bib54","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.012_bib55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","article-title":"Translating p53-based therapies for cancer into the clinic","volume":"24","author":"Peuget","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2026.01.012_bib56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.annonc.2026.01.012_bib57","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.22.01285","article-title":"A first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas","volume":"41","author":"Gounder","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.01.012_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103636","article-title":"A first-in-human phase I study of a novel MDM2\/p53 inhibitor alrizomadlin in advanced solid tumors","volume":"9","author":"Zhang","year":"2024","journal-title":"ESMO Open"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.01.012_bib59","article-title":"PYNNACLE phase 2 clinical trial of rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation","volume":"43","author":"Schram","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.012_bib60","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3390\/cells11050794","article-title":"Effects of the mutant TP53 reactivator APR-246 on therapeutic sensitivity of pancreatic cancer cells in the presence and absence of WT-TP53","volume":"11","author":"Abrams","year":"2022","journal-title":"Cells"},{"issue":"14","key":"10.1016\/j.annonc.2026.01.012_bib61","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.01.012_bib62","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41418-023-01122-3","article-title":"The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells","volume":"30","author":"Wang","year":"2023","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.annonc.2026.01.012_bib63","doi-asserted-by":"crossref","first-page":"S535","DOI":"10.1016\/j.annonc.2024.08.2162","article-title":"691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation","volume":"35","author":"Schram","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib64","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1038\/s41467-025-59282-4","article-title":"P53 Protein degradation redefines the initiation mechanisms and drives transitional mutations in colorectal cancer","volume":"16","author":"Herranz-Montoya","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib65","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.012_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1158\/0008-5472.CAN-25-1054","article-title":"Targeted degradation of mutant p53 reverses the pro-oncogenic dominant-negative effect","volume":"85","author":"Gencel-Augusto","year":"2025","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2026.01.012_bib67","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.chembiol.2024.04.002","article-title":"Molecular glues for protein-protein interactions: progressing toward a new dream","volume":"31","author":"Konstantinidou Markella","year":"2024","journal-title":"Cell Chem Biol"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.012_bib68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.012_bib69","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","article-title":"Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer","volume":"13","author":"Adams","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib71","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-022-01616-7","article-title":"Wnt signaling in colorectal cancer: pathogenic role and therapeutic target","volume":"21","author":"Zhao","year":"2022","journal-title":"Mol Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2026.01.012_bib72","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.3390\/ijms24076733","article-title":"Wnt signaling inhibitors and their promising role in tumor treatment","volume":"24","author":"Pe\u0107ina-\u0160laus","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.annonc.2026.01.012_bib73","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1078-0432.CCR-21-3018","article-title":"Comprehensive analysis of R-spondin fusions and RNF43 mutations implicate novel therapeutic options in colorectal cancer","volume":"28","author":"Seeber","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","article-title":"Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours","volume":"125","author":"Rodon","year":"2021","journal-title":"Br J Cancer"},{"issue":"65","key":"10.1016\/j.annonc.2026.01.012_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc6424","article-title":"Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape","volume":"6","author":"Takeuchi","year":"2021","journal-title":"Sci Immunol"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2026.01.012_bib76","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1016\/j.annonc.2021.08.1039","article-title":"517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours","volume":"32","author":"Cook","year":"2021","journal-title":"Ann Oncol"},{"issue":"8 suppl 2","key":"10.1016\/j.annonc.2026.01.012_bib77","article-title":"Abstract CT032: Phase 1\/2 trial of the TBL1 inhibitor, tegavivint, in advanced hepatocellular carcinoma (aHCC)","volume":"85","author":"Hsieh","year":"2025","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib78","first-page":"1","article-title":"DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B","volume":"16","author":"Lee","year":"2025","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.annonc.2026.01.012_bib79","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.ajpath.2018.05.014","article-title":"Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database","volume":"188","author":"Moek","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.annonc.2026.01.012_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104165","article-title":"9O Phase I\/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: updated safety and pharmacokinetic analysis","volume":"10","author":"Almhanna","year":"2025","journal-title":"ESMO Open"},{"issue":"15","key":"10.1016\/j.annonc.2026.01.012_bib81","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"suppl 6","key":"10.1016\/j.annonc.2026.01.012_bib82","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1158\/1538-7445.AM2024-3124","article-title":"Abstract 3124: MRG006A, a novel glypican-3-targeting antibody-drug conjugate, demonstrated potent anti-tumor activity and good safety profile in preclinical studies","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.01.012_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114698","article-title":"177 (PB165): ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models","volume":"211","author":"Madera","year":"2024","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.annonc.2026.01.012_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"8 suppl 2","key":"10.1016\/j.annonc.2026.01.012_bib85","doi-asserted-by":"crossref","first-page":"LB193","DOI":"10.1158\/1538-7445.AM2025-LB193","article-title":"Abstract LB193: Developing protein degraders to target the \u201cundruggable\u201d MYC","volume":"85","author":"Lampropoulou","year":"2025","journal-title":"Cancer Res"},{"issue":"8 suppl 1","key":"10.1016\/j.annonc.2026.01.012_bib86","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1158\/1538-7445.AM2025-7006","article-title":"Abstract 7006: TY-2719, a potent and selective broad-spectrum mutation-effective EGFR-PROTAC molecule, attenuates acquired resistance to 3rd-generation EGFR TKIs","volume":"85","author":"Liang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.01.012_bib87","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"npj Precis Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.012_bib88","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib89","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.annonc.2026.01.012_bib90","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.012_bib91","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1038\/s41467-024-49932-4","article-title":"Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses","volume":"15","author":"Malli Cetinbas","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.annonc.2026.01.012_bib92","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"issue":"6382","key":"10.1016\/j.annonc.2026.01.012_bib93","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.012_bib94","article-title":"Bispecific antibodies in hematologic and solid tumors : current landscape and therapeutic advances","volume":"45","author":"Guidi","year":"2025","journal-title":"Am Soc Clin Oncol Educ B"},{"issue":"8","key":"10.1016\/j.annonc.2026.01.012_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.annonc.2026.01.012_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1545270","article-title":"SynNotch CAR-T cell, when synthetic biology and immunology meet again","volume":"16","author":"Shirzadian","year":"2025","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.annonc.2026.01.012_bib97","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"14","key":"10.1016\/j.annonc.2026.01.012_bib98","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in ecurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.annonc.2026.01.012_bib99","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.012_bib100","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.annonc.2026.01.012_bib101","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.annonc.2026.01.012_bib102","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.01.012_bib103","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.012_bib104","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:14:55Z","timestamp":1784704495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426000396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":104,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0923753426000396"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.01.012","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in targeting the untouchables: emerging approaches for hard-to-drug cancer targets","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}